Alvotech and Sandoz Agree to Sell and Market Biologics in Canada, Australia, and New Zealand

Alvotech, a biotech company, has signed agreements with Swiss pharma firm Sandoz to sell and market several potential biosimilar products in Canada, Australia, and New Zealand. The agreements are part of Alvotech's strategy to ensure access to high-quality biosimilars before receiving regulatory approval. The products include a potential eye disease treatment and three potential treatments for infectious and inflammatory diseases. Sandoz will be responsible for registering and marketing the products, while Alvotech will handle development, clinical trials, and manufacturing.